You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
|
|---|---|
| Published in |
Clinical Cancer Research, December 2019
|
| DOI | 10.1158/1078-0432.ccr-19-2177 |
| Pubmed ID | |
| Authors |
Darren R. Hargrave, Eric Bouffet, Uri Tabori, Alberto Broniscer, Kenneth J. Cohen, Jordan R. Hansford, Birgit Geoerger, Pooja Hingorani, Ira J. Dunkel, Mark W. Russo, Lillian Tseng, Kohinoor Dasgupta, Eduard Gasal, James A. Whitlock, Mark W. Kieran |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 14% |
| Portugal | 1 | 14% |
| Unknown | 5 | 71% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 84 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 13% |
| Student > Ph. D. Student | 8 | 10% |
| Other | 7 | 8% |
| Student > Doctoral Student | 6 | 7% |
| Student > Bachelor | 4 | 5% |
| Other | 14 | 17% |
| Unknown | 34 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 21% |
| Biochemistry, Genetics and Molecular Biology | 11 | 13% |
| Neuroscience | 4 | 5% |
| Immunology and Microbiology | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 12 | 14% |
| Unknown | 33 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2023.
All research outputs
#1,171,777
of 24,564,172 outputs
Outputs from Clinical Cancer Research
#789
of 13,049 outputs
Outputs of similar age
#28,752
of 470,010 outputs
Outputs of similar age from Clinical Cancer Research
#29
of 201 outputs
Altmetric has tracked 24,564,172 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,049 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 470,010 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 201 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.